New research indicates that individuals who come off popular slimming jabs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who stop traditional diet and exercise regimens.
Research printed in a prominent health publication shows that while obese people frequently drop a large proportion of their total mass while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"Users using such drugs must be aware of the danger of quick rebound weight gain when the treatment concludes," cautioned researcher Dr. Susan Jebb.
Such speed of recovery suggests a reversion to pre-treatment mass within about one and a half years.
Comparing Treatments
The analysis, which looked at 37 of trials involving thousands of patients, compared the effects of the injectable medications with conventional dieting.
Researchers note that people who shed pounds through dieting generally experience a more gradual weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Quick Rebound
Nutrition scientists propose the mechanism of the jabs is key to understanding the amplified rebound.
These medications imitate a body's own chemical called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production may cause the system to produce less of its endogenous hormone, and may also diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication results in appetite is unsuppressed, making binge eating much more probable."
A Chronic Disease?
Health authorities advise the jabs for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, considering the likelihood of relapse, the therapy should be considered long-term.
This perspective is echoed by drug manufacturers, who state that the findings "emphasize the chronic nature of obesity," akin to managing diseases like diabetes.
Patient Experiences
Users who have stopped the medication describe a intense resurgence of hunger.
"I experienced a switch that goes on and you become extremely hungry," said one woman.
This difficulty is compounded if individuals have not established lasting lifestyle or habit modifications during therapy.
Growing Adoption
Figures show that a significant number of adults in the UK have tried these injections in the last 12 months, with desire being substantial.
- Adoption is higher among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
In conclusion, researchers stress that while these medications are powerful agents for weight loss, they are not a standalone cure and maintained weight loss hinges on integrated behavioural support.
